Company intelligence / Profile preview

ReFuel America

San Francisco, California, USA

Ownership: Private
Development stage: Other

Overview

Refuel Therapeutics is a biotechnology company focused on developing next-generation cell therapies for cancer. The company's platform technology aims to overcome T-cell exhaustion, a major hurdle in the effectiveness of CAR-T and TCR-T therapies, particularly in solid tumors. By "refueling" T-cells through metabolic and epigenetic reprogramming, Refuel seeks to enhance the persistence and potency of immune cells within the immunosuppressive tumor microenvironment. The company was co-founded by renowned immunotherapy expert Dr. Crystal Mackall and is backed by prominent life science investors.

Therapeutic areas: Oncology
Modalities: Cell therapyCAR-T cell therapyGene therapy
Industry: Biotech

Beyond the preview

Go deeper on ReFuel America.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ReFuel America.

Explore the full profile